Follow The Filings

COAG Hemab Therapeutics

Hemab Therapeutics earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 10 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by COAG's executives, directors and 10% owners in the last 12 months, from their Form 4s

All COAG insider trades
  • $55.5M bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Ra Capital Management, L.P. 10% owner, +3 joint filers
    Buy
    $1.7M 67,669 shares at $24.97 +1.1% to stake
    Traded Jun 15–16 Filed Jun 17
  2. Ra Capital Management, L.P. 10% owner, +3 joint filers
    Buy
    $120K 4,798 shares at $24.96 +0.1% to stake
    Traded May 19–20 Filed May 21
  3. Ra Capital Management, L.P. 10% owner, +3 joint filers
    Buy
    $159K 6,387 shares at $24.90 +0.1% to stake
    Traded May 12 Filed May 14
  4. Ra Capital Management, L.P. 10% owner, +3 joint filers
    Buy
    $1.3M 51,258 shares at $24.75 +0.8% to stake
    Traded May 7–11 Filed May 11
  5. Ra Capital Management, L.P. Director, +5 joint filers
    Buy
    $52.2M 2,840,429 shares at $18.39 +82% to stake
    Traded May 4–6 Filed May 6

Also filed in the last 12 months, not counted as buying or selling: 6 conversions.

SEC filings

Recent issuer filings from EDGAR, 21 shown.

Filed Form Detail Links
8-K 5.02
SCHEDULE 13G —
SCHEDULE 13G —
SCHEDULE 13G —
8-K 2.02,9.01
10-Q
SCHEDULE 13G —
SCHEDULE 13G —
SCHEDULE 13G —
8-K 2.02,9.01
10-Q
SCHEDULE 13D —
SCHEDULE 13G —
8-K 5.02
SCHEDULE 13G —
8-K 5.03,8.01,9.01
424B4
S-1/A
S-1/A
S-1/A
S-1

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.